2BBBullish & Bearish
Health Care

Intellia Therapeutics, Inc. (NTLA) Stock Score & Signals

Intellia Therapeutics, Inc. (NTLA) trades on NASDAQ. It operates in the Health Care sector, Biotechnology industry. Its current 2BB score is 49 out of 100.

About Intellia Therapeutics, Inc.

Intellia Therapeutics, Inc. is an American clinical-stage biotechnology company focused on developing novel, potentially curative therapeutics leveraging CRISPR-based technologies. The company's in vivo programs use intravenously administered CRISPR as the therapy, in which the company's proprietary delivery technology enables highly precise editing of disease-causing genes directly within specific target tissues. Intellia's ex vivo programs use CRISPR to create the therapy by using engineered human cells to treat cancer and autoimmune diseases.

2BB score and signals

Intellia Therapeutics, Inc.’s current 2BB score is 49 out of 100, built from the signal categories below.

SignalScoreReading
Activity51Moderate
Momentum29Weakening
Financial strength21Weak
Quality100Very Strong
Risk44Moderate

Company facts

CEOJohn Leonard
HeadquartersCambridge, Massachusetts, United States
Founded2014
Employees377
52-week range$7.95 – $28.24

Recent earnings

Report dateEPS actualEPS estimateRevenue actualRevenue estimate
2027-02-24-0.7952$19.51M
2026-11-04-0.8171$10.67M
2026-08-06-0.8152$14.18M
2026-05-11-0.81-0.9321$15.05M$15.09M